Key result
First-trimester exposure to ACE inhibitors was associated with an increased risk of major congenital malformations compared with no antihypertensive exposure (RR 2.71; 95% CI 1.72 to 4.27).
Why the study?
Does maternal exposure to ACE inhibitors during the first trimester of pregnancy increase the risk of major congenital malformations in infants?
Population
29,507 infants enrolled in Tennessee Medicaid and born between 1985 and 2000 for whom there was no evidence…
Comparison
Maternal exposure to ACE inhibitors during the… vs No maternal exposure to antihypertensive drugs…
Design
Cohort
Follow-up
first year of life
Authors
Loading...
First-trimester ACE inhibitor exposure was associated with increased malformations; leaves open causality and should not yet change practice.
Cohort (n=29,507)
Does maternal exposure to ACE inhibitors during the first trimester of pregnancy increase the risk of major congenital malformations in infants?
Relative Risk: 2.71 (95% CI 1.72–4.27)
First-trimester exposure to ACE inhibitors is associated with a significantly increased risk of major congenital malformations, indicating they should be avoided during early pregnancy.
Cooper et al. (2006) conducted a cohort in Maternal ACE inhibitor use during pregnancy (n=29,507). ACE inhibitors vs. No exposure to antihypertensive medications was evaluated on Major congenital malformations (RR 2.71, 95% CI 1.72 to 4.27). First-trimester exposure to ACE inhibitors was associated with an increased risk of major congenital malformations compared with no antihypertensive exposure (RR 2.71; 95% CI 1.72 to 4.27).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: